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ment with aging biobanks, considering these as a sign
of respect for specific problems of people of older ages
such as higher disease burdens. 
Conclusion: Knowledge of biobanks was found to be
limited. Participants were positive toward the setting
up of biobanks in general and patient-centered aging
biobanks in particular. Knowledge about biobanks and
acceptance were higher among participants with high-
er education years.
Keywords: Biobank; Aging; Ethics; Patient awareness.
INtrODUctION
Biobanks for research (BBR) consist in organized reposi -
tories of biological samples with associated data for re-
search purposes1. Such collections can be representa-
tive of a population or a subset of a population2.
Samples stored in BBR, including those of human ori-
gin, can consist in organs, tissues, biofluids (e.g. blood,
urine) and genetic materials (e.g. DNA)3,4. Human bio -
logical samples may be obtained from a variety of
sources: from healthy volunteers, patients or retrieved
post-mortem5. Furthermore, sample collections can be
population-based or disease-specific, originating from
individuals with different demographics, health, be-
haviours and lifestyles4. Classification of human sam-
ple-related BBR varies6. Nonetheless, three major types
can be identified: (i) population-based biobanks whose
primary goal is to obtain biomarkers of population
identity and susceptibility (typically from the DNA of
large numbers of healthy donors), representative of a
country/region/ethnic cohort; (ii) disease-oriented
biobanks for epidemiology studies and (iii) disease-ori-
ented general biobanks7–9. In terms of ownership, BBR
can be public, private or result from partnerships across
different sectors and be held by hospitals, research ins -
titutes, pharmaceutical companies and patient organiza-
tions4. BBR governance models also vary substantially10. 
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AbstrAct 
Objective: Biobanks for research (BBR) have enormous
value for research, including those specifically orien -
ted to chronic diseases. Knowing public attitudes and
perceptions is key to design and implement patient-
centered BBR. We assessed patient awareness, percep-
tion and choices among rheumatology outpatients re-
garding aging biobanking activities.
Methods:We conducted a cross-sectional survey of pa-
tients, aged 50 or older, attending an outpatient
rheumatology tertiary department. Demographic data
and perceptions about biobanking were collected and
statistical analysis was performed. 
Results: 132 valid questionnaires were obtained (mean
age: 63.4; 68.2% female; mean education years: 8.35).
61.7% of respondents did not know the specific term
“biobank”, 57.7% knew they could donate biological
material for BBR, 89.9% agreed with these infrastruc-
tures and 88.3% would consider participation Those
participants with more years of education were more
knowledgeable and prone to biobank participation.
Willingness to participate in BBR was mainly related
(86.4%) to the advancement of scientific knowledge
and not individual gain. Scientific research institutes
were indicated as the most adequate institutions to
manage BBR. Informed consent, anonymity and confi-
dentiality ranked as top requisites for biobank partici-
pation. 61.3% of respondents expressed their agree-
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Growing numbers of BBR have been created
throughout Europe in the last decades11–15. The imple-
mentation of a vast range of BBR in Europe and else-
where, coupled with the large number of shared sam-
ples have been widely considered as a fundamental
resource for scientific research, potentiating the col-
lective capacity to understand human biology and
medicine while contributing to fight disease and im-
prove quality of life. 
In parallel, as a result of relevant developmental ef-
forts, Portuguese BBR have also been created and im-
plemented16. Subsequently, a national biobank consor-
tium (Biobanco.pt) has been set up to inventory national
infrastructures, catalogue samples, harmonise proce-
dures and promote national and international research17.
In parallel and in line with their relevant role for
healthcare, BBR participation and BBR inclusion in pa-
tient-centered health systems has been studied and de-
bated5,7,18. 
To design and develop patient-centered biobanks,
public awareness, perceptions and choices regarding
these fundamental infrastructures must be evaluated
and understood19. More than acting as mere sample
donors, members of the public can, and perhaps should,
act as partners or collaborators as their perspective is a
valuable resource for the biobank20. Previous studies
have shown that citizens express a variable willingness
to participate in medical research21–28. However, their an-
swer is generally positive when they were specifically
questioned about donating samples to BBR24,29–36.
Despite these largely positive attitudes towards par-
ticipation, BBR, particularly those of national and in-
ternational scope, face significant challenges37. In par-
ticular, ethical, legal and social issues (ELSI) of BBR
deserve particular attention15,38.
Relevant ELSI of BBR include (but are not exclusive
to): i) the protection of the rights to autonomy, confi-
dentiality and privacy of participants while also re-
specting the public interest of scientific research; ii) se-
lecting the method, scope, level of detail, and
periodicity of informed consent for BBR; iii) security
measures that should be adopted; iv) balancing non-
commercial use of human biological material for scien -
tific research purposes and the development of com-
mercial products directly arising from stored and
shared samples; v) promoting public trust and inclu-
sion; vi) incentives for donor participation; vii) own-
ership, governance and management issues; viii) access
to research results; ix) ensuring maximum quality of
sample preservation and management, while facilitat-
ing sample access and sharing7,8,29,33,39–44.
In particular, the European Commission 2010 Eu-
robarometer report on European citizens attitudes to-
wards biotechnology has provided relevant insights
into the level of awareness towards biobanking activi-
ties in Europe45. In Portugal, less than one in five re-
spondents (19%) had heard of biobanks prior to the
survey (EU average – 34%)45. Moreover, it was found
that for EU citizens consent is fundamental for BBR
(ibid., p.142) and medical doctors were preferred to
protect the public interest, with researchers being the
second most preferred group. The intensity of this pref-
erence was most pronounced in Portugal (60%) (ibid.,
p.147).  Willingness to provide personal information to
biobanks was mixed (ibid., p.144) despite concerns re-
garding the collection of personal information in
biobanks (ibid., p.149). Additionally, EU citizens were
generally in favour of data and materials being ex-
changed across biobanks in different Member States,
with opinions varying significantly between countries
on this specific matter (ibid., p.151)45.
A decade has passed since this seminal European re-
port.  Nevertheless, doubts about ELSI continue to in-
fluence patient acceptability to tissue banking programs
and transparency remains key to foster acceptance of
the ways a biobank is developed and used7.
In the last decade, biobanks have gained significant
relevance and momentum46. In particular, public per-
ceptions about BBR, and specifically those oriented to
chronic diseases populations, have gathered heighte -
ned attention3,24,29,30,33–35,47.Furthermore, even more re-
cently, the importance of BBR for the understanding of
prevalent conditions and multimorbidity of middle-
aged and older adults has been stressed48. Epidemio-
logical findings resulting from biobanks for aging have
also been published in crucial areas such as prostate
cancer and the relation between statin use and cancer
development49–51.
These advances have led to the development of
biobanks dedicated to aging research7,52. Some of these
BBR focus on the collection of samples from middle age
or elderly participants and due to this fact elicit new
ELSI or exacerbate general ones53–58.
However, despite the established need for public ac-
ceptance and involvement and the increasing attention
to aging research biobanks and healthy aging research
in general, to the best of our knowledge no study has
evaluated the public's perceptions of a BBR dedicated
to aging, in particular in a rheumatology context.
Hence, while generally aiming to fill that gap, the
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present study specifically aims to:
1. identify rheumatology patients’ awareness, percep-
tions, concerns and preferences regarding BBR and
their willingness to donate human biological sam-
ples for biomedical research;
2. understand the individual perception of rheumato -
logy patients regarding relevant BBR ELSI;
3. investigate rheumatology patient’s opinion and ac-
ceptance regarding BBR especially dedicated to the
study of aging and aging populations. 
mAterIAl AND methODs
stUDy DesIgN, methODs AND prOceDUres 
We designed a cross-sectional study in a random sam-
ple of tertiary rheumatology outpatients from the
Rheumatology Unit of the Egas Moniz University Hos-
pital, in Lisbon, Portugal. Data was collected through
the application of a self-administered questionnaire.
Questionnaire quality and adequacy was guaranteed
by a cyclical process of revision, update and improve-
ment, involving experts (researchers and physicians).
The final questionnaire consisted in 20 closed-ended
and semi-closed-ended questions, divided in four
parts: the first and second parts (questions 1-10) as-
sessed the respondents’ opinions about “General aware-
ness and perception of biobanking activities” and “Pa-
tient perceptions regarding biobank participation in
BBR”; the third part (questions 11 and 12) focused ex-
clusively on “Perceptions about biobanks dedicated to
the study of aging”; the fourth part, including 8 ques-
tions (A-H) assessed respondents demographic char-
acteristics. In some questions, the respondents were
given the opportunity to write comments to comple-
ment their answer.
The questionnaires were provided to the participants
by a researcher not involved in providing patient care
or working in biobank management. Participants re-
ceived the questionnaire in a rheumatology clinic wait-
ing room setting and prior to participation received
complete written information about the study context,
objectives, research team, data anonymity and future
research results communication.
Inclusion criteria: adult rheumatology outpatients
aged 50 years or older who were able to read and un-
derstand the provided study information. Exclusion
criteria: place of residence outside Portugal. 
The questionnaire was applied to a random sample
of one hundred and fifty-three subjects between March-
-October 2016. The final response rate was 86.3% 
(n = 132). Twenty-one questionnaires were excluded
according to the following criteria: (i) blank question-
naires: 3; (ii) questionnaires where the socio-demo-
graphic section was more than 25% incomplete (two or
more answers) or which included no indication of re-
spondents  age: 15; (iii) individuals under 50 years old:
4; (iv) more than one questionnaire filled with the same
handwriting: 1. Inconsistent or contradictory answers
to questions 3-4 and 11-12 were not considered. 
Ethics: The procedures followed were in accordance
with the Helsinki Declaration of 1975/83, the Interna-
tional Ethical Guidelines for Epidemiological Studies
(2009) and the standards of the responsible local com-
mittee. The study protocol, information to the partici-
pant and questionnaire were submitted for review to
the competent institutional review board (Ethics Com-
mittee, Egas Moniz University Hospital, Lisbon, Por-
tugal), with subsequent approval (approval number
20170700050). 
Statistics: frequency distribution tables with counts
and percentages were used to describe categorical varia -
bles as well as mean and standard deviation for nu-
merical variables. Variables were crossed and tested for
statistical associations with chi-square test/Fisher ex-
act test. All hypothesis tests were two-sided for 5%
signi ficance level. All data was coded and analysed us-
ing SPSS Statistics 23® software. 
resUlts
DemOgrAphIc chArActerIzAtION Of the
stUDy pOpUlAtION 
Demographic characteristics of the surveyed popula-
tion are presented in Table I. Survey respondents were
mostly women (sex ratio 2.1:1, female: male, n=90 and
42, respectively) with a mean age of 63.98 years old.
Middle school was the most prevalent education level
(mean of 8.35 education years) and the majority of re-
spondents were already retired (53.8%).
geNerAl AwAreNess AND perceptION Of
bIObANks fOr reseArch 
The first objective of our study was to evaluate the
gene ral understanding of rheumatology patients re-
garding biobanks for research. To achieve this goal, we
first asked respondents whether they were aware of the
possibility of storing biological material for scientific
research purposes (Question - Q1). As a result, we
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obser ved that more than half of the respondents
(57.7%) were informed about this possibility (Table II).
However, when asked whether they knew what a
biobank is (Q2), only 38.0% of those inquired res -
ponded affirmatively (Table II). 
Importantly, knowledge about the term biobank cor-
related with education years in a statistically significant
manner, as those with 10 or more years of education
(secondary school level in Portugal) exhibited higher
knowledge (51.9%) in comparison to those with 0 to
9 years education years (28.9%) (Table III). 
Knowledge about what a biobank is might also cor-
relate with age (45.6% of respondents between 50 and
64 years of age said they knew what a biobank is while
only 30.0% responded yes to the same question in the
65 years old or older group), suggesting this might be a
variable of interest for future studies in higher samples
(in our study these differences were below statistical sig-
nificance, p=0,101). Knowledge about the term biobank
did not depend on the gender of the respondent.
We also set out to evaluate overall perceptions re-
garding biobanking activities. In order to achieve this
objective, we asked respondents whether they agreed
with the existence of organized repositories of biolog-
ical samples and associated clinical data for research
purposes (Q3). Unambiguously, 89.9% of the respon-
dents stated their agreement with the existence of such
research infrastructures (Table II). Agreement seemed
to diminish with age and increase with education years,
but these correlations were below statistical significance
(p=0,100 and p=0,111, respectively).  Again, the gen-
der of the respondent did not seem to affect answers to
this question (Table III). 
In probing the basis for agreement or disagreement
with BBR, we found a mixture of altruistic and indi-
vidualistic reasons (Q4). Largely, respondents said their
agreement was based on the contribution of BBR to the
advancement of scientific knowledge, even though that
advancement might not benefit them directly (86.4%)
(Table II). Nonetheless, 66.1% of those inquired ex-
pressed that they agreed with the existence of BBR be-
cause the quality of care available to them in the future
could be improved. On the contrary, the majority of
those who declared not to agree with BBR stated as rea-
sons for their disagreement the preference for animal
studies or in vitro models (61.5%). A fraction of the
same population (46.2%) also declared that they
though that biobanks should only be used for medical
purposes and not research (Table II)
Lastly, in order to complete our characterization of
the general public perception of biobanks we asked
which entities or organisations are adequate to mana -
ge BBR (Q5). The vast majority of those inquired
(89.1%) responded that scientific research institutes
(which in Portugal are autonomous and not equivalent
to research buildings of universities) were adequate or-
ganisations to manage biobanks, followed by hospitals
(42.9%), universities (28.6%), biotechnology or phar-
maceutical companies (12.6%), community health
centers (4.2%), other governmental entities (1.7%) and
patient associations (0.8%) (Table II). 
pAtIeNt reqUIremeNts regArDINg bIObANk
pArtIcIpAtION AND pUblIc trUst IN bIObANks 
Globally, 88.3% of the patients surveyed considered
participating in a biobank (Table IV). Willingness to par-
ticipate correlated with education years in a statistical-
ly significant manner, as those with 10 or more years of
education (secondary school level in Portugal) are more
willing to participate (97.8%) in comparison to those
with 0 to 9 years education years (80.7%) (Table V). 
Participation might also correlate with younger age
(93.0% of respondents between 50 and 64 years of age
versus 82.6% in the 65 years old or older group), but
in our study this difference was below statistical sig-
nificance (p=0,129). As was the case with other vari-
ables, willingness to participate in biobanks did not de-
pend on the gender of the respondent (Table VI).
In terms of requisites for participation, 72.0% of pa-
tients identified explicit authorization/informed con-
sent, 52.5% prefer to participate in a study relevant for
their individual health and 50.0% stated that they
would require no negative health effects resulting from
tAble I. sOcIO-DemOgrAphIc chArActerIstIcs
Of respONDeNts
Socio-demographic variables Results
Age [mean (min-max)] 63.98 (50-93)
Sex ratio M/F (%) 31.8%/68.2%






min - minimum, max – maximum; M – masculine, F – feminine
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their participation (Table IV). 39.0% of patients ex-
pressed they would only participate in BBR in case of
benefits for their individual treatment, 29.7% high-
lighted the possibility of sample destruction in case
they change their mind, 21.2% value the absence of
extra harvest of biological samples for research pur-
poses, 16.9% demand keeping property rights over the
samples, 7.6% would only participate if they had the
right to profit from the research results only 4.2% re-
quired remuneration or equivalent benefits in retribu-
tion for BBR participation (Table IV).
In terms of management as a requisite for participa-
tion (Q8), 43.3% of respondents required a public
biobank, 32.5% expressed that they would donate to
a biobank that was run by a physician or a researcher
they knew, 27.5% required a biobank that is governed
by an entity of their trust, while only 4.2% stated their
requirement of a private biobank. Indifference toward
the different management options was expressed by
45.8% of those inquired (Table IV).
Regarding the security measures as a requisite for
BBR participation (Q9), confidentiality/anonymity
tAble II. geNerAl AwAreNess AND perceptION Of bbr
Valid answers Yes No Indifferent
(n) (n) (n) (n)
Q1. Did you know that biological materials (blood, urine 130 57.7% (75) 42.3% (55) –
or others) could be stored and used for research purposes? 
Q2. Do you know what a biobank is? 128 38.3% (49) 61.7% (79) –
Q3. A biobank for scientific research consists in an 119 89.9% (107) 0.8%(1) 9.2%(11)
organized repository of biological materials and 
associated clinical information, for sharing between 
scientific researchers to improve their studies. 
Do you agree with such projects?
Q4. In accordance with the previous answer, please 118
indicate the reasons for your choice
(Please select all valid options)
Agreement with the existence of BBR 
It can improve the healthcare I might receive in the future 66.1% (78) – –
It might advance scientific knowledge even if I do not 86.4% (102) – –
benefit directly 
Other (state which) 4.2% (5) – –
Disagreement with the existence of BBR 13
Biological materials are part of a person’s body and should 46.2% (6) – –
only be used for disease diagnostics and treatments and 
should be destroyed immediately after
Scientific studies should be performed using solely animal 
or in vitro models 61.5% (8) – –
Other (state which) 0% (0) – –
Q5. Please indicated which organizations you think are 119 –
adequate to manage a BBR
Scientific research institutes 89.1% (106) – –
Hospitals 42.9% (51) – –
Universities 28.6% (34) – –
Biotechnology or pharmaceutical companies 12.6% (15) – –
Community health centers 4.2% (5) – –
Other governmental entities 1.7% (2) – –
Patient associations 0.8% (1) – –
Other (state which) 0% (0) – –
THE OffICIAL JOURNAL Of THE PORTUgUESE SOCIETy Of RHEUMATOLOgy
223
Cordeiro JV et al
tAble III. geNerAl AwAreNess AND perceptION Of bbr AccOrDINg tO sex, Age AND eDUcAtION yeArs
Valid answers Yes No Indifferent
(n) (n) (n) (n)
Q2. Do you know what a biobank is? 128 38.3% (49) 61.7% (79) –
Female 87 37.9% (33) 62.1% (54) –
Male (p = 0,999) 41 39.0% (16) 61.0% (25) –
50-64 years old 68 45.6% (31) 54.4% (37) –
65 years old or older (p = 0,999) 60 30.0% (18) 70.0% (42) –
0 to 9 years education 76 28.9% (22) 71.1% (54) –
10 years education or more (p = 0,009) 52 51.9% (27) 48.1% (25) –
Q3. A biobank for scientific research consists in an 119 89.9% (107) 0.8% (1) 9.2% (11)
organized repository of biological materials and 
associated clinical information, for sharing between 
scientific researchers to improve their studies. 
Do you agree with such projects?
Female 82 89.0% (73) 1.2% (1) 9.8% (8)
Male (p = 0,760) 37 91.9% (34) 0.0% (0) 8.1% (3)
50-64 years old 66 93.9% (62) 1.5% (1) 4.5% (3)
65 years old or older (p = 0,100) 53 84.9% (45) 0.0% (0) 15.1% (8)
0 to 9 years education 67 86.6% (58) 0.0% (0) 13.4% (9)
10 years education or more (p = 0,111) 52 94.2% (49) 1.9% (1) 3.8% (2)
about participation and confidentiality about indivi -
dual clinical data were selected as top priorities (by
65.3% and 58.5% of respondents, respectively) (Table
III). Moreover, 35.6% said they valued the impossibil-
ity to share their donated samples for studies for which
they did not consent (which implies a denial of open
consent models that have been largely debated and
supported in the biobanking discourse (59–61). 22.9%
of surveyed patients stated their requirement for re-
consent in case of publication of research results. Only
14.4% of respondents stated they viewed direct secu-
rity measures (such as alarms, locks or passwords) as
necessary for participation, and 11.0% accentuated the
impossibility of sample sharing with different re-
searchers as a required protection arrangement. 
Notably, in terms of public trust, an overwhelming
majority of respondents (94.2%) stated they would
publicize the existence of a specific biobank so that 
other people could participate (Table IV).
pAtIeNt perceptIONs AbOUt bIObANks 
DeDIcAteD tO the stUDy Of AgINg
In order to assess patient perceptions about biobanks for
aging research we asked respondents their opinion
about a biobank dedicated to the study of aging, which
only collected samples from people of older ages (Q11).
Most respondents (61.3%) expressed their agreement
with such research infrastructure and research practice,
while only 9.4% stated their disagreement (Table VI). 
Agreement seemed to increase with education years,
but this correlation was below statistical significance
(p=0,125).  Both age and gender of the respondent did
not seem to affect answers to this question (Table VI)
Subsequently, we went on to probe further the rea-
sons for agreement and disagreement with aging
biobanks (Q12). The majority of those who agree
(76.3%) indicated that people of older ages have hi -
 gher disease burdens, which specially justifies their
study (Table IV). Importantly, 51.5% also responded
that such research infrastructures and practices were a
sign of respect for the particular problems of people of
older ages, while 6.3% selected other reasons of their
own creation (Table VI). For those who disagree, 53.5%
considered that the elderly should not be differentiat-
ed from those of any other age. In parallel, 25.6% of
those who disagree adopted a more paternalistic ap-
proach stating that people of older age are more vul-
nerable and unable to make free and informed deci-
sions. Also, 16.3% of those who disagree stated that
people of older age have higher disease burdens and
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therefore focus should be on treatment and not re-
search. Finally, 9.3% indicated that their disagreement
was based on other reasons (Table VI). 
DIscUssION 
Biobanks have become much more prevalent in the last
years. More recently, biobanks dedicated to aging re-
search have been developed, which begs the question of
whether chronic patients, in particular rheumatology
patients support these infrastructures. Hence, the pur-
pose of this study was to identify participants’ percep-
tions and concerns as participants in BBR and willing-
ness to donate human biological samples for biomedical
research, while exploring preferences regarding BBR
tAble IV. pAtIeNt reqUIremeNts regArDINg bIObANk pArtIcIpAtION AND pUblIc trUst IN bIObANks
Valid answers Yes No
(n) (n) (n)
Q6. Would you consider participating in a biobank by donating biological 103 88.3% (91) 11.7% (12)
material (blood, urine, other) for scientific research purposes?
Q7. Please indicate the essential requisites for your participation in a 118
biobank. (Please select all valid options)
Explicit authorization/informed consent 72.0% (85) –
The study of a disease or condition that affects me 52.5% (62) –
Absence of negative health effects resulting from my participation 50.0% (59) –
Benefits for my individual treatment 39.0% (46) –
Possibility of sample destruction in case I change my mind 29.7% (35) –
No extra sample collection procedures required (using samples collected 
for diagnostic purposes) 21.2% (25) –
Keeping property rights over the samples 16.9% (20) –
Right to profit from the results of the research 7.6% (9) –
Remuneration or other equivalent benefit 4.2% (5) –
Q8. In your opinion how should a biobank be managed for you to 120
consider donating your samples? (Please select all valid answers)
Public biobank 43.3% (52) –
Indifferent, I would donate my samples independently of biobank 40.0% (48) –
management 
Biobank managed by a physician or researcher that I know 32.5% (39) –
Biobank managed by an entity that I trust 27.5% (33) –
Indifferent, I would never donate my samples to a biobank 5.8% (7) –
Private biobank 4.2% (5) –
Q9. In your opinion, which would be the required security measures for 118
you to consider donating your samples? (Please select all valid answers)
Confidentiality about my participation or anonymity 65.3% (77) –
Confidentiality about my clinical data 58.5% (69) –
Impossibility to share donated samples for studies for which I did not 35.6% (42) –
consent 
Need to reconsent for publication of research results using the samples 22.9% (27) –
I donated 
Existence of direct security measures for the protection of my samples 14.4% (17) –
(e.g. alarms, locks or passwords)
Impossibility of sample sharing with different researchers 11.0% (13) –
Q10. Would you accept to publicize the existence of a specific biobank 103 94.2%(97) 5.8%(6)
so that other people could participate?
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ownership and management. We also set out to unders -
tand rheumatology patients  support and perceptions
regarding BBR exclusively dedicated to aging. 
In terms of the general understanding of rheuma-
tology hospital outpatients regarding biobanking ac-
tivities we observed that more than half of the respon-
dents were informed about the possibility to store
biological material for scientific research purposes but
only 38.3% was aware of the term biobank. Notwith-
standing, knowledge about this term increased signif-
icantly (to 51.9%) among those with secondary school
studies. These results demonstrate that despite its
growing application in research, clinical, academic and
commercial settings, the term “biobank” remains large-
ly unknown. In order to address this challenge and
raise BBR awareness, scientists, researchers and
biobank professionals should consider active strategies
to inform the public about the existence, relevance and
potential of these infrastructures. Particularly, local, re-
gional and national public information campaigns as
well as participatory policies and citizen science pro-
grams should be considered62,63. 
We also found that willingness to contribute to BBR
is high: 88.3% agreed potentially to provide biological
materials for the constitution of a BBR. These rates are
in the higher range in comparison with studies from
other countries about biobanking participation and are
extraordinarily high among those with secondary
school studies (97.8%)3,19,29,30,32–36,47. Notably, the vast
majority of our respondents agreed to advertise a
biobank so that others could participate (94.2%). Ta -
ken together these results indicate that the overall trust
in biobanks for research purposes is very high amongst
the rheumatology outpatients we surveyed. 
The average age of the rheumatology patients we
surveyed may also justify the high predisposition to
participation rate, since it has been shown that both
the likelihood of donating a biospecimen and clinical
health information to a BBR are reportedly higher for
middle and older ages24,31,32,64. This fact might be ex-
plained by Erikson’s theory of generativity, i.e. an in-
creasing concern with age for guiding and caring for the
next generation24. Curiously, we found a tendency (not
statistically significant) for a higher willingness to par-
ticipate among the younger respondents of the study
group (50-64 years old). Future studies in higher sam-
ples should clarify the issue of age-dependent willing-
ness to participate in BBR.
In line with previous studies, it was evident in our
study that the decision to donate samples to a BBR is
primarily based on altruistic reasons24. Nonetheless, the
fact that the large majority of rheumatology patients
we surveyed (88.2%) do not expect remuneration or
economic gain from participation in BBR does not
mean that they do not have an expectation of getting
something in return. The study of a disease or condi-
tion that affects them and benefit for their individual
treatment were indicated as essential requisites for par-
ticipation for 52.5% and 39.0% of respondents, res -
pectively. 
Positive attitudes toward BBR and trust in biobank
owners are vital for the future of biobanking re-
search65,66. The same can be concluded from our study
as 60.0% of the rheumatology outpatients we surveyed
indicated that they preferred to donate samples when
that element of trust is present (be it a known re-
searcher or a physician or a trusted entity). Also, we
found that rheumatology outpatients largely trust re-
tAble V. pAtIeNt reqUIremeNts regArDINg bIObANk pArtIcIpAtION AND pUblIc trUst IN bIObANks
AccOrDINg tO sex, Age AND eDUcAtION yeArs
Valid answers Yes No
(n) (n) (n)
Q6. Would you consider participating in a biobank by donating 103 88.3% (91) 11.7% (12)
biological material (blood, urine, other) for scientific research purposes?
Female 70 88.6% (62) 11.4% (8)
Male (p = 0,999) 33 87.9% (29) 12.1% (4)
50-64 years old 57 93.0% (53) 7.0% (4)
65 years old or older (p = 0,129) 46 82.6% (38) 17.4% (8)
0 to 9 years education 57 80.7% (46) 19.3% (11)
10 years education or more (p = 0,011) 46 97.8% (45) 2.2% (1)
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search institutes and hospitals to manage BBR, which
is in line with other research results in the past67. Al-
though 45.8% of our respondents willing to donate
samples were indifferent to the nature of BBR manage-
ment, those who expressed preference for donating
samples to a private biobank were very few (4.2%) in
comparison to those who preferred donating to a pub-
lic biobank (43.3%), which is in line with other stu dies
elsewhere68 and the 2010 EU Eurobarometer45.
Evaluating motivations and attitudes toward BBR is
important but understanding barriers and facilitators of
public participation is also fundamental. Notably, pre-
vious studies have shown that informed consent is one
of the most relevant and discussed elements for bal-
anced and participatory constitution of bio -
banks25,28,43,69,70.
Unsurprisingly, explicit informed consent was the
essential requisite for participation most selected by
our respondents. Moreover, informed consent for sam-
ple sharing within specific research studies was also
significantly identified by rheumatology patients as be-
ing essential. This observation implies a tendency to-
wards denial of open consent models that have been
largely debated with some degree of support in the
tAble VI. pAtIeNt perceptIONs AbOUt bIObANks DeDIcAteD tO the stUDy Of AgINg
Valid answers Yes No Indifferent
(n) (n) (n) (n)
Q11. What do you thing about a biobank which only 106 61.3% (65) 9.4% (10) 29.2% (31)
collected samples from people of older ages for aging 
research purposes?
Female 73 60.3% (44) 11.0% (8) 28.8% (21)
Male (p = 0,727) 33 63.6% (21) 6.1% (2) 30.3% (10)
50-64 years old 61 62.3% (38) 8.2% (5) 29.5% (18)
65 years old or older (p = 0,879) 45 60.0% (27) 11.1% (5) 28.9% (13)
0 to 9 years education 59 54.2% (32) 8.5% (5) 37.3% (22)
10 years education or more (p = 0,125) 47 70.2% (33) 10.6% (5) 19.1%(9)
Q12. In accordance with the previous answer, please 
indicate the reasons for your choice 
(Please select all valid options)
Agreement with the existence of aging BBR 97
As they age people have higher disease burdens, which 76.3% (74) – –
specially justifies their study 
It is a sign of respect for the issues of people of more 51.5% (50) – –
advanced age 
Other (state which): “the possibility to prevent diseases 6.3% (6) – –
in people of younger ages and the improvement of the 
quality of life of the elderly”
Disagreement with the existence of aging BBR 43
People of older age usually have higher disease burdens 16.3% (7) – –
and therefore should only be treated, there is no reason 
for them to be studied
People of older ages are the exactly the same as those of 53.5% (23) – –
any other age and therefore deserve no different treatment
People of older age are sometimes more vulnerable and do 25.6% (11) – –
not have the conditions to make free and informed decisions
Other (state which): “diseases at old age are many times 9.3% (4) – –
the result of unsolved or unfound problems at young ages 
or that the focus should be on prevention to avoid 
problems of older ages not on the study of the latter”
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biobanking discourse29,43,59. It is also noteworthy that a
non-negligible proportion of our respondents (22.9%)
indicated the need for reconsent in case of publication
of research results, suggesting that clarification of this
possibility when recruiting participants for BBR is
paramount. Also, in line with previous studies, confi-
dentiality and data protection measures (both regard-
ing participation and clinical data) were referred in our
study as relevant guarantees for BBR participation65,68,71.
Finally, we also aimed to evaluate the level of support
for biobanks dedicated to aging research, in particular
those who collect samples from people of an older age.
Such research infrastructures have gathered pace re-
cently and may prove important for chronic disease re-
search, and rheumatology research in particular53,54,56.
Our results are encouraging on that front as they indi-
cate that the population of rheumatology outpatients
surveyed favour and value the existence of aging
biobanks that collect samples from people of older ages.
Such acceptance was mainly justified by higher disease
burdens in this population but more than 50% inter-
prets this idea as a sign of respect. Significant concerns
remain, however, in particular in relation to the pro-
tection of those who are most vulnerable and their po-
tential discrimination.  As this study only surveyed pa-
tients attending a Rheumatology outpatient clinic in
only one tertiary hospital it would be interesting to in-
vestigate possible discrepancies amongst the attitudes
of patients depending on different disorders and resi-
dence areas in the future.
cONclUsIONs
In conclusion, our study constitutes a comprehensive
analysis of public perceptions and patient choices re-
garding general biobanks and biobanks for aging re-
search purposes among rheumatology outpatients. To
the best of our knowledge this is the first study where
these variables were assessed in this population. Al-
though awareness is still suboptimal, BBR are highly
regarded health infrastructures with enormous poten-
tial for further patient-centered development. Taken
together, our results indicate that the population of hos-
pital outpatients surveyed favour and value the exis-
tence of biobanks in general and aging biobanks in par-
ticular. Addressing concerns, their motives and
advancing public education in these areas will enhance
participation and engagement, which are critical to the
future foundation and design of aging BBR.  More than
acting as mere donors, patients can and should be in-
volved in structured and harmonised national and in-
ternational biobanking activities72,73 as their voice and
perspective can be a valuable resource for the biobank.
We believe our study contributes to highlight the im-
portance of patient centered biobanks, particularly for
aging and chronic disease research.
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